Please try another search
Protagenic Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 5 million compared to USD 3.56 million a year ago. Basic loss per share from continuing operations was USD 1.15 compared to USD 0.82 a year ago. Diluted loss per share from continuing operations was USD 1.15 compared to USD 0.82 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | ||||
Operating Income | -1.21 | -1.43 | -1.14 | -0.739 |
Net Income | -1.68 | -1.4 | -1.21 | -0.718 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 4.32 | 5.43 | 6.92 | 7.67 |
Total Liabilities | 0.655 | 1.28 | 1.51 | 1.25 |
Total Equity | 3.67 | 4.15 | 5.41 | 6.41 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -1.14 | -0.656 | -1.53 | -0.372 |
Cash From Investing Activities | 2.28 | 0.591 | 1.61 | 0.295 |
Cash From Financing Activities | ||||
Net Change in Cash | 1.13 | -0.066 | 0.081 | -0.077 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review